Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | PYCR1 | P32322 | 3/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21878591 | 0.98 | CYP2A6 (0.40) | CYP2A6CCR5PYCR1DGAT1HTR2A | |
| SCHEMBL30758577 | 0.82 | CA1 (0.35) | PYCR1 | |
| SCHEMBL25385457 | 0.80 | PTGDR2 (0.38) | PYCR1 | |
| SCHEMBL29303374 | 0.80 | GABRA1 (0.42) | CYP2A6CCR5PYCR1HTR2ADPP4 | |
| SCHEMBL30975561 | 0.80 | GABRA1 (0.42) | CYP2A6CCR5PYCR1HTR2ADPP4 | |
| SCHEMBL20818008 | 0.78 | MPO (0.42) | HTR2ATRPM8TAAR1 | |
| SCHEMBL30476381 | 0.78 | MPO (0.42) | HTR2ATRPM8TAAR1 | |
| SCHEMBL20818407 | 0.77 | MPO (0.36) | DPP4 | |
| SCHEMBL3390800 | 0.73 | CYP2A6 (0.48) | CYP2A6CCR5HTR2ATRPM8TAAR1 | |
| SCHEMBL110765 | 0.72 | PYCR1 (0.46) | CYP2A6PYCR1DGAT1HTR2ATRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129395-A1 | BTK INHIBITORS | GWYNANT THERAPEUTICS, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | NR1H2, NR1H3, NR1H4 | CYP2A6 524/4885CCR5 1083/4885PYCR1 3403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.